
|Videos|July 10, 2018
Treatment Options for Relapsed/Refractory Solid Tumors in Pediatric and Young Adult Patients
Author(s)Ami V. Desai, MD, MSCE
Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.
Advertisement
Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.
Currently, Desai says the best treatment option for these patients is surgery. There are also a number of inhibitors for some gene fusions found in these types of malignancies, but not all patients are able to enroll in these studies.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5


































